For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) ...